Lenaster (Hydrocortisone Sodium Phosphate)

The active ingredient binds to intracellular glucocorticoid receptors in ocular tissues. This complex alters gene expression, suppressing the production of inflammatory cytokines, prostaglandins, and leukotrienes. The result is decreased vascular permeability, reduced leukocyte infiltration, and overall mitigation of ocular inflammation.

The specific dosing regimen for Lenaster is determined by the prescribing eye‑care professional based on the condition being treated, severity, and patient response. The prescriber will provide detailed instructions on the number of drops, frequency, and duration of therapy.

Safety data for hydrocortisone sodium phosphate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers will evaluate individual circumstances before prescribing.

To request Lenaster, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lenaster delivers hydrocortisone sodium phosphate, a relatively short‑acting corticosteroid with a favorable safety profile for short‑term use. Compared with more potent agents such as dexamethasone or prednisolone acetate, it may have a lower risk of intra‑ocular pressure rise but may require more frequent dosing for equivalent anti‑inflammatory effect.

Lenaster should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperature fluctuations. Do not freeze the solution, and discard any vial that appears cloudy or contaminated.

Lenaster is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill the prescribed number of drops without touching the tip to the eye or surrounding structures. Follow the prescriber’s dosing schedule precisely.

Serious risks include a sustained increase in intra‑ocular pressure leading to glaucoma, development of cataracts with prolonged use, secondary ocular infections, and rare severe allergic reactions such as angio‑edema. Patients should report any sudden vision changes, eye pain, or signs of infection promptly.

Lenaster should be avoided in individuals with known hypersensitivity to hydrocortisone sodium phosphate or any component of the formulation, active ocular infections, or uncontrolled glaucoma. It is also contraindicated in patients receiving other potent ocular steroids unless specifically directed by a specialist.